Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Influence of Enzalutamide on Cabazitaxel Pharmacokinetics: a Drug-Drug Interaction Study in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients.

Belderbos BPS, Bins S, van Leeuwen RWF, Oomen-de Hoop E, van der Meer N, de Bruijn P, Hamberg P, Overkleeft ENM, van der Deure WM, Lolkema MP, de Wit R, Mathijssen RHJ.

Clin Cancer Res. 2018 Feb 1;24(3):541-546. doi: 10.1158/1078-0432.CCR-17-2336. Epub 2017 Nov 17.

PMID:
29150561
2.

Factors Affecting the Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer.

Hussaarts KGAM, van Leeuwen RWF, Mathijssen RHJ.

JAMA Oncol. 2018 Feb 1;4(2):263-264. doi: 10.1001/jamaoncol.2016.7019. No abstract available.

PMID:
29098281
3.

Drug-drug interactions in pediatric oncology patients.

Balk TE, van der Sijs IH, van Gelder T, Janssen JJB, van der Sluis IM, van Leeuwen RWF, Engels FK.

Pediatr Blood Cancer. 2017 Jul;64(7). doi: 10.1002/pbc.26410. Epub 2017 Feb 16.

PMID:
28205376
4.

Tyrosine Kinase Inhibitors and Proton Pump Inhibitors: An Evaluation of Treatment Options.

van Leeuwen RWF, Jansman FGA, Hunfeld NG, Peric R, Reyners AKL, Imholz ALT, Brouwers JRBJ, Aerts JG, van Gelder T, Mathijssen RHJ.

Clin Pharmacokinet. 2017 Jul;56(7):683-688. doi: 10.1007/s40262-016-0503-3.

5.

Genome-wide methylome analysis using MethylCap-seq uncovers 4 hypermethylated markers with high sensitivity for both adeno- and squamous-cell cervical carcinoma.

Wang R, van Leeuwen RW, Boers A, Klip HG, de Meyer T, Steenbergen RD, van Criekinge W, van der Zee AG, Schuuring E, Wisman GB.

Oncotarget. 2016 Dec 6;7(49):80735-80750. doi: 10.18632/oncotarget.12598.

6.

Reply to N. Singh et al.

van Leeuwen RWF, van Gelder T, Aerts JG, Mathijssen RHJ.

J Clin Oncol. 2016 Nov 20;34(33):4054. doi: 10.1200/JCO.2016.68.9356. Epub 2016 Oct 31. No abstract available.

PMID:
27551130
7.

Discovery of new methylation markers to improve screening for cervical intraepithelial neoplasia grade 2/3.

Boers A, Wang R, van Leeuwen RW, Klip HG, de Bock GH, Hollema H, van Criekinge W, de Meyer T, Denil S, van der Zee AGJ, Schuuring E, Wisman GBA.

Clin Epigenetics. 2016 Mar 9;8:29. doi: 10.1186/s13148-016-0196-3. eCollection 2016.

8.

Influence of the Acidic Beverage Cola on the Absorption of Erlotinib in Patients With Non-Small-Cell Lung Cancer.

van Leeuwen RW, Peric R, Hussaarts KG, Kienhuis E, IJzerman NS, de Bruijn P, van der Leest C, Codrington H, Kloover JS, van der Holt B, Aerts JG, van Gelder T, Mathijssen RH.

J Clin Oncol. 2016 Apr 20;34(12):1309-14. doi: 10.1200/JCO.2015.65.2560. Epub 2016 Feb 8. Erratum in: J Clin Oncol. 2016 Aug 10;34(23):2806.

PMID:
26858332
9.

Drug-drug interactions associated with kinase inhibitors: highlighting a new resource for oncologists and clinical pharmacists.

Gelderblom H, Köhne CH, Launay-Vacher V, van Leeuwen RW.

Ann Oncol. 2016 Apr;27(4):752. doi: 10.1093/annonc/mdw019. Epub 2016 Jan 19. No abstract available.

PMID:
26787233
10.

Stability of colistimethate sodium in a disposable elastomeric infusion device.

Abdulla A, van Leeuwen RW, de Vries Schultink AH, Koch BC.

Int J Pharm. 2015;486(1-2):367-9. doi: 10.1016/j.ijpharm.2015.04.008. Epub 2015 Apr 8.

PMID:
25863116
11.

Reply to the letter to the editor 'potential clinical relevant drug-drug interactions: comparison between different compendia, do we have a validated method?' by Conde-Estévez et al.

van Leeuwen RW, Mathijssen RH, Jansman FG, van Gelder T.

Ann Oncol. 2015 Jun;26(6):1272-3. doi: 10.1093/annonc/mdv169. Epub 2015 Apr 6. No abstract available.

PMID:
25846553
12.

Drug-drug interactions in patients treated for cancer: a prospective study on clinical interventions.

van Leeuwen RW, Jansman FG, van den Bemt PM, de Man F, Piran F, Vincenten I, Jager A, Rijneveld AW, Brugma JD, Mathijssen RH, van Gelder T.

Ann Oncol. 2015 May;26(5):992-7. doi: 10.1093/annonc/mdv029. Epub 2015 Jan 26.

PMID:
25628444
13.

Drug interactions between tyrosine-kinase inhibitors and acid suppressive agents: more than meets the eye-Authors' reply.

van Leeuwen RW, van Gelder T, Mathijssen RH, Jansman FG.

Lancet Oncol. 2014 Oct;15(11):e470-1. doi: 10.1016/S1470-2045(14)70459-0. No abstract available.

PMID:
25281462
14.

DNA methylation analysis in self-sampled brush material as a triage test in hrHPV-positive women.

Boers A, Bosgraaf RP, van Leeuwen RW, Schuuring E, Heideman DA, Massuger LF, Verhoef VM, Bulten J, Melchers WJ, van der Zee AG, Bekkers RL, Wisman GB.

Br J Cancer. 2014 Sep 9;111(6):1095-101. doi: 10.1038/bjc.2014.392. Epub 2014 Jul 17.

15.

Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective.

van Leeuwen RW, van Gelder T, Mathijssen RH, Jansman FG.

Lancet Oncol. 2014 Jul;15(8):e315-26. doi: 10.1016/S1470-2045(13)70579-5. Review.

PMID:
24988935
16.

Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugs.

van Leeuwen RW, Brundel DH, Neef C, van Gelder T, Mathijssen RH, Burger DM, Jansman FG.

Br J Cancer. 2013 Mar 19;108(5):1071-8. doi: 10.1038/bjc.2013.48. Epub 2013 Feb 14.

17.

Use of hormonal contraceptives and risk of HIV-1 transmission.

van Leeuwen RW, de Vries F.

Lancet Infect Dis. 2012 Jul;12(7):508-9; author reply 510-1. doi: 10.1016/S1473-3099(12)70113-5. No abstract available.

PMID:
22742629
18.

Tissue plasminogen activator (tPA) in the management of predominantly hemorrhagic age-related macular degeneration, milligram/milliliter or microgram/milliliter?

Boone NW, van Leeuwen RW.

Clin Ophthalmol. 2012;6:145. doi: 10.2147/OPTH.S28071. Epub 2012 Jan 19. No abstract available.

19.

Intravenous fat emulsion therapy for intentional propafenone intoxication.

ten Tusscher BL, Beishuizen A, Girbes AR, Swart EL, van Leeuwen RW.

Clin Toxicol (Phila). 2011 Aug;49(7):701. doi: 10.3109/15563650.2011.597033. Epub 2011 Aug 8. No abstract available.

PMID:
21819289
20.

Potential drug interactions in cancer therapy: a prevalence study using an advanced screening method.

van Leeuwen RW, Swart EL, Boven E, Boom FA, Schuitenmaker MG, Hugtenburg JG.

Ann Oncol. 2011 Oct;22(10):2334-41. doi: 10.1093/annonc/mdq761. Epub 2011 Feb 22.

PMID:
21343376
21.

Potential drug interactions and duplicate prescriptions among ambulatory cancer patients: a prevalence study using an advanced screening method.

van Leeuwen RW, Swart EL, Boom FA, Schuitenmaker MS, Hugtenburg JG.

BMC Cancer. 2010 Dec 13;10:679. doi: 10.1186/1471-2407-10-679.

Supplemental Content

Loading ...
Support Center